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Introduction: The aim of this retrospective cohort study was to determine the  
potential diagnostic yield of prenatal whole exome sequencing in fetuses with structural 
anomalies on expert ultrasound scans and normal chromosomal microarray results.
Material and methods: In the period 2013-2016, 391 pregnant women with fetal 
ultrasound anomalies who received normal chromosomal microarray results, were 
referred for additional genetic counseling and opted for additional molecular test-
ing pre- and/or postnatally. Most of the couples received only a targeted molecular 
test and in 159 cases (40.7%) whole exome sequencing (broad gene panels or open 
exome) was performed. The results of these molecular tests were evaluated retro-
spectively, regardless of the time of the genetic diagnosis (prenatal or postnatal).
Results: In 76 of 391 fetuses (19.4%, 95% CI 15.8%-23.6%) molecular testing pro-
vided a genetic diagnosis with identification of (likely) pathogenic variants. In the 
majority of cases (91.1%, 73/76) the (likely) pathogenic variant would be detected by 
prenatal whole exome sequencing analysis.
Conclusions: Our retrospective cohort study shows that prenatal whole exome sequenc-
ing, if offered by a clinical geneticist, in addition to chromosomal microarray, would no-
tably increase the diagnostic yield in fetuses with ultrasound anomalies and would allow 
early diagnosis of a genetic disorder irrespective of the (incomplete) fetal phenotype.
K E Y W O R D S
diagnostic yield, fetal anomalies, prenatal diagnosis, prenatal whole exome sequencing 
testing, ultrasound anomalies, whole exome sequencing
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1  | INTRODUC TION
The incidence of congenital structural malformations is approximately 
3% in pregnancies worldwide.1 Most of these malformations are 
detectable during the second trimester of pregnancy, half of them 
as early as in the first trimester.2 There is a wide range of potential 
outcomes for fetuses with malformations depending on the type of 
malformation, whether an anomaly is isolated or not, and the potential 
underlying genetic etiology.1 Congenital malformations vary from ei-
ther isolated mild anomalies (ie, postaxial polydactyly) to potentially le-
thal, multisystem anomalies. When ultrasound anomalies are detected, 
prenatal cytogenetic diagnosis is routinely offered. In such pregnan-
cies a chromosomal microarray on DNA isolated from chorionic villi 
or amniocytes is recommended for optimal detection of chromosomal 
aberrations.3 It was shown that chromosomal microarray improves 
diagnosis by up to 6.8% over conventional karyotyping, by detecting 
(sub)microscopic pathogenic copy number variants in isolated and non-
isolated anomalies.4 Although microarray analysis enables testing with 
much higher resolution than conventional karyotyping, the cause of 
the abnormal phenotype remains unknown in ~75% of the pregnant 
women referred due to an ultrasound anomaly.5 In many prenatal diag-
nostic centers these pregnant women are currently offered additional 
genetic counseling. When the fetus shows specific features that allow 
targeted DNA testing, a targeted molecular test can be performed. 
When the targeted analysis shows normal results, the fetus may have a 
non-syndromic birth defect or an undiagnosed genetic disorder that is 
not detectable with conventional karyotyping, chromosomal microar-
ray or targeted DNA analysis.
In contrast to chromosomal microarray, which offers genome-wide 
detection of chromosomal aberrations (genotype first approach), there 
is currently only a limited number of targeted DNA tests for monogenic 
disorders that are possible during pregnancy because of the limited 
prenatal phenotype. Although prenatal imaging (ultrasound, MRI) has 
dramatically improved, the clinical information obtained is still limited 
in comparison with postnatal phenotyping. If a pregnancy is continued 
and a child with congenital anomalies is born, sometimes the pheno-
type is evident after birth and (further) targeted genetic testing be-
comes feasible. Because the fetal phenotype is limited to ultrasound 
findings we anticipate that, similar to chromosomal microarray, routine 
prenatal whole exome sequencing (WES) will improve prenatal diag-
nostic yield. The molecular characterization of a disease has funda-
mental implications in the clinical setting. The etiologic definition of 
the prenatal phenotype is useful to discuss the parents’ reproductive 
choices (eg, continuation or termination of pregnancy) of the current 
affected pregnancy. Not only reproduction autonomy is facilitated, but 
this knowledge provides optimal birth management (eg, planned birth 
at a university hospital, planned cesarean section) and allows specific 
early interventions after birth for the identified disease. Furthermore, 
it withdraws ineffective or potentially harmful investigations and/or 
treatments after birth.6 Parents can be provided with detailed prog-
nostic counseling useful to predict potential complications. And finally, 
molecular diagnosis enables recurrence risk assessment as well as pre-
natal or preimplantation diagnosis in future pregnancies.6,7
To assess the potential diagnostic yield of prenatal WES a retro-
spective analysis of a cohort of fetuses with ultrasound anomalies, 
but normal prenatal microarray result, was performed and the re-
sults are presented here.
2  | MATERIAL AND METHODS
We performed a retrospective analysis investigating the potential 
influence of WES on the diagnostic yield of prenatal genetic diag-
nostics. In the period 2013-2016, 391 pregnant women with fetal 
ultrasound anomalies who received normal prenatal microarray re-
sults were referred for additional genetic counseling and opted for 
additional molecular testing pre- and/or postnatally. Only fetal cases 
that underwent invasive prenatal sampling were included in this co-
hort. The data that support the findings of this study are available 
in the Supporting information (Tables S1-S5, Figure S1). Additionally, 
variants are submitted to the DECIPHER database (see Supporting 
information, Appendix S1).
2.1 | Routine diagnostic follow up in pregnancies 
with ultrasound anomalies in this cohort
Fetal anomalies from our cohort were suspected by routine ultra-
sound scanning, mostly in the setting of second-trimester ultra-
sound screening, and diagnosed by expert ultrasound examination 
in a center for prenatal diagnosis. Prospective parents were offered 
pretest counseling on the routine test characteristics and potential 
benefits and disadvantages for prenatal genetic testing and invasive 
testing (chorionic villi sampling or amniocentesis). Twin pregnancies 
where both fetuses had different anomalies and were both sampled, 
were counted as two separate individuals. After invasive testing, 
in some cases rapid aneuploidy detection preceded the microarray 
analysis. If no pathogenic chromosomal aberration was found, addi-
tional genetic counseling was considered and, if feasible, a molecular 
test was offered.
2.2 | Targeted molecular testing
Targeted molecular testing (TMT) included a targeted test for an indi-
vidual disorder, either through Sanger sequencing of a single gene or 
Key Message
Prenatal whole exome sequencing, if offered by a clinical 
geneticist in case of both isolated and multiple ultrasound 
anomalies, would detect (likely) pathogenic variants in 
18.7% of fetuses and allow early diagnosis of a genetic dis-
order irrespective of the (incomplete) fetal phenotype.
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multiple genes associated with the same disorder or through  targeted 
analysis of multiple genes through next-generation  sequencing 
(NGS) panels for individual disorders. TMT was performed in cases 
with a fetal phenotype suggestive for a specific monogenetic disor-
der (eg, Sanger sequencing of FGFR3 when the fetus presents with a 
skeletal dysplasia suggestive for achondroplasia).
2.3 | Broad molecular testing
Broad molecular testing includes NGS multi-gene panel analysis tar-
geting multiple disorders (broad gene panels) or analyzing the whole 
exome (WES). Broad molecular testing was performed when the 
ultrasound anomalies were non-suggestive for a specific disorder, 
but suspect for a genetic cause. Broad gene panels allowed analy-
sis of many genes associated with various symptoms. Some of these 
panels were improved over time by expanding the panel with extra 
(newly discovered) well-described genes. For the general description 
of the available gene panels see Supporting information (Table S1). 
The multiple congenital malformations panel and intellectual dis-
ability panel were the largest gene panels used. Molecular testing 
was only performed after thorough counseling (including informa-
tion about all possible outcomes) and written informed consent from 
both parents. The multiple congenital malformations and intellectual 
disability panel as well as open exome analysis were performed on 
trios (fetus and both parents) for filtering and analysis. In a few cases 
the open exome was analyzed: sequencing of the exome (the exons 
of the genome) outside the previously performed gene panel. There 
are, however, certain parts of the exome that are not (fully) covered 
with this test.
Fetal DNA for molecular testing was extracted from amniocytes, 
chorionic villi or from fetal tissues when available after termination 
of pregnancy or after birth (skin biopsy or umbilical cord blood/
biopsy).
2.4 | Reported variants
The variants were classified according to Standards and Guidelines 
for the Interpretation of Sequence Variants: A Joint Consensus 
Recommendation of the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology.8,9 Relevant 
findings included the class 5 (pathogenic) and class 4 (likely patho-
genic) variants. Cases with class 3 variants (variant of uncertain sig-
nificance) were excluded, unless they were found together with a 
pathogenic variant on the second allele in case of a recessive disor-
der matching the fetal phenotype.
2.5 | Cohort selection
A total of 391 couples who opted for additional molecular testing 
either during pregnancy or during postnatal follow up were included 
in this study. All ultrasound fetal anomalies were included regardless 
of the severity of these anomalies to create a clinically representa-
tive cohort. Some parents postponed (targeted or broad) molecular 
testing until after the child was born as they, for example, chose ter-
mination of the pregnancy based on the ultrasound abnormalities. 
The results of all performed molecular tests were evaluated retro-
spectively, regardless of the time of the genetic diagnosis (prenatal 
or postnatal). The patients were grouped based on their ultrasound 
anomalies similar to Shaffer et al and Raniga et al (see Supporting 
information, Table S2)10,11:
1. 251 fetuses showed one or more major abnormalities (possibly 
in combination with soft markers) that only involved one organ 
system (eg, bell-shaped thorax and short femur). These systems 
included the central nervous system, musculoskeletal system, 
cardiovascular system, craniofacial system, gastrointestinal sys-
tem and urogenital system. Notably, this group also contained 
the strictly isolated anomalies (eg, isolated nuchal translucency 
>3.5 mm, isolated cleft lip) (isolated single system).
2. 26 patients were referred due to prenatal diagnosis for one single 
major fetal abnormality accompanied by one or more soft markers 
involving a different organ system (eg cleft lip and single umbili-
cal artery) (multiple anomalies (1 system + soft marker in another 
organ system).
3. 93 fetal cases with at least two major malformations in differ-
ent organ systems (multisystem malformations, for example, 
ventriculomegaly and ventricular septal defect) (multiple system 
anomalies).
4. Only 21 fetal cases were enrolled with ultrasound abnormalities 
consisting exclusively of soft markers (mostly due to echogenic 
bowel) (soft marker(s) only [SM]).
2.6 | Statistical analyses
The percentage of cases with relevant clinical (likely) pathogenic 
single nucleotide variants in fetuses with ultrasound anomalies 
and with normal chromosomal microarray results is reported with 
Wilson score 95% confidence intervals, which have a good coverage 
probability even for small samples and estimated percentages close 
to zero or one hundred.12 Computations were performed using the 
Epitools epidemiological calculator (Sergeant, ESG, 2018. Epitools 
Epidemiological Calculators. Ausvet; available at: http://epito ols.
ausvet.com.au).
2.7 | Ethical approval
All presented data are anonymous and do not allow identification of 
the individual patients and were obtained during routine diagnostic 
procedures. Patients are informed that we may investigate/publish 
their medical data as long as all data remain anonymous and can-
not lead to the identification of the individual persons. Our research 
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represents a retrospective patient records study that does not fall 
under the scope of the WMO (The Medical Scientific Research 
with Humans Act), and therefore it did not need to be assessed by 
an accredited Medical Ethical Committee or the CCMO (Central 
Committee on Research Involving Human Subjects). According to the 
Research Codes of Erasmus MC and the FMWV Code of Conduct for 
Health Research the data that cannot be traced to an individual may 
be used for research.
3  | RESULTS
Three hundred and ninety-one fetal cases where molecular testing 
was performed were enrolled. Figure S1 (in the Supporting infor-
mation) illustrates the diagnostic process and tests preceding (open) 
exome analysis (WES). As WES was not yet routinely performed, 
in most cases only TMT was performed. In 50/309 (16.2%, 95% CI 
12.5%-20.7%) cases referred for TMT a (likely) pathogenic variant 
was found. Forty-seven cases underwent additional broad molecu-
lar testing. In total, in 159 cases broad molecular testing using NGS 
panel and/or open exome sequencing analysis WES (43/159) were 
performed. Of these 43 cases, open exome analysis was preceded 
by broad molecular testing in 30 cases. In 26/159 (16.4%, 95% CI 
11.4%-22.9%) a (likely) pathogenic variant was found. Overall, mo-
lecular testing yielded a definitive diagnosis by identifying a (likely) 
pathogenic variant in 76 of the 391 enrolled cases (19.4%, 95% CI 
15.8%-23.6%). Three cases showed hypomethylation of H19 causing 
Silver-Russell syndrome, which cannot be detected by offering pre-
natal WES. Therefore, we calculated that in 18.7% (95% CI 15.1%-
22.8%) of cases (73/391) prenatal WES would detect the (likely) 
pathogenic variant if offered prenatally. The syndromes/diseases 
that were most often found were Noonan syndrome (n = 13) and 
cystic fibrosis (n = 3). However, in our cohort only targeted testing 
for Noonan syndrome (in the first or early second trimester in cases 
with neck anomalies) would be feasible before WES request. Cystic 
fibrosis was often tested in late second trimester, therefore it is not 
feasible to exclude cystic fibrosis first and then request prenatal 
WES. If all 13 cases of Noonan syndrome were excluded in the first 
trimester, the expected diagnostic yield would be 60/378 (15.9%, 
95% CI 12.5%-19.9%) (if only the remaining 378 [ie, 391–13] fetuses 
were further tested with WES).
Table 1 summarizes cases where a syndromic disorder was de-
tected per category of ultrasound anomaly. All phenotypic case de-
tails are shown in the Supporting information (Table S3). Table S4 
shows further individual case details and the (likely) pathogenic vari-
ants that were detected in this cohort.
The diagnostic yield rates were subdivided into major catego-
ries shown in the Supporting information (Table S2). Most (likely) 
pathogenic findings were identified in fetuses with multiple system 
anomalies, 27/93 (29.0%, 95% CI 20.8%-38.9%) (Table 2). The ma-
jority of fetuses in our cohort showed (apparently isolated) single 
system malformations. In 16.7% of these fetuses (42/251, 16.7%, 
95% CI 12.6%-21.8%) a molecular diagnosis was made. Figure 1 
presents the number and percentage of cases with molecular 
diagnosis in fetuses per ultrasound category: fetuses with multiple 
system anomalies, fetuses with multiple anomalies (1 system + soft 
marker(s) in another organ, multiple anomalies), fetuses with anom-
alies isolated single system and fetuses with (multiple) soft markers. 
Figure 2 shows the number and percentage of abnormal cases per 
ultrasound anomaly within the isolated single system category. The 
results in fetuses with isolated nuchal translucency, hygroma colli 
and hydrops fetalis were also given separately. The highest percent-
age of abnormal cases was found in cases with hydrops fetalis and in 
cases with musculoskeletal anomalies. Unfortunately, the individual 
groups were too small to calculate statistically significant percent-
ages. More cases are needed to study the prevalence of pathogenic 
variants in these subgroups. Interestingly in four out of six consan-
guineous couples that were tested, a recessive disorder explaining 
the fetal phenotype was detected (F32, F38, F44, F58, Supporting 
information, Tables S3 and S4).
Only 14/76 cases were diagnosed during pregnancy (Supporting 
information, Table S3), because prenatal WES was not offered before 
2017. In the remaining cases, it was not feasible to achieve diagnosis 
before birth or before termination of pregnancy. In the remaining 
fetuses, diagnosis was made either after termination of pregnancy 
(parents did not want to wait for further testing or achieving results 
was not feasible before 24 weeks of gestation) or after birth when 
new phenotypic information became available. Due to the obstacles 
mentioned above the time span from invasive sampling to receiving 
a positive molecular result from the laboratory varied from 7 days to 
1001 days (median = 200, mean = 271, data not shown, calculated 
from the date of invasive sampling until the reporting date).
In our cohort, only in 36 cases ultrasound anomalies were diag-
nosed in the third trimester. In the large majority of cases (355/391, 
90.8%) ultrasound anomalies were detected in the first or second 
trimester. Therefore invasive sampling was performed before the 
24th week of gestation. Prenatal WES, if directly offered, may sig-
nificantly contribute to pregnancy management (Supporting infor-
mation, Table S5).
3.1 | Unexpected diagnoses, so called 
incidental findings
Unexpected diagnoses are results that seem to be unrelated to 
the primary indication of the molecular test and may or may not 
be relevant to the patient's health.13 In our cohort, one inciden-
tal finding was documented by performing gene panels (F60, see 
Supporting information, Table S3). The fetus had a neural tube 
defect and growth restriction. The multiple congenital malfor-
mations panel showed a pathogenic variant in homozygous form 
in the MANB gene, causing β-mannosidosis. β-Mannosidosis is 
a rare lysosomal storage disorder of glycoprotein catabolism 
caused by a deficiency of lysosomal β-mannosidase activity (MIM 
#248510). β-Mannosidosis is not associated with structural fetal 
malformations. The patients’ phenotype is variable and the age of 
     |  5DIDERICH Et al.
TA B L E  1   Summary of cases: fetal phenotypes at the time of invasive sampling and the syndromic disorders detected by various 
molecular tests in the presented cohort
Indication for prenatal 
testing Gene
Molecular diagnosis
Phenotypic MIM number Indication for prenatal testing Gene
Diagnosis
Phenotypic MIM number
Musculoskeletal (17) Hydrops (7)
Short long bones with 
restrained curvature
DYNC2H1 Jeune syndrome (short-rib 
thoracic dysplasia 3 with 
or without polydactyly) 
#613091





Signs of skeletal dysplasia DYNC2H1 Jeune syndrome 
(asphyxiating thoracic 
dystrophy 3) #613091
Hydrops fetalis UNC13D Hemophagocytic 
lymphohistiocytosis type 
3 #608898










IUGR BRCA2 Fanconi anemia #605724
Signs of skeletal dysplasia COL1A1 Osteogenesis imperfecta 
type 2 #166210
IUGR H19 Silver-Russell syndrome 
#180680
Signs of skeletal dysplasia, 
short ribcage, short long 
bones with restrained 
curvature
COL1A1 Osteogenesis imperfecta 
type 2 #166200
IUGR DDX11 Warsaw breakage 
syndrome #613398
Signs of skeletal dysplasia, 






Short long bones COL2A1 Spondyloepiphyseal 
dysplasia congenital 
(SEDC) #183900
Unilateral multicystic renal 
dysplasia and pyelectasis 
with echogenic cortex left
HNF1B Renal cysts and diabetes 
syndrome (RCAD) 
#137920
Contracture of the hands 
(flexion of the wrists), short 
long bones
B3GALT6 Spondyloepimetaphyseal 
dysplasia with joint laxity, 
type 1, with or without 
fractures #271640
Ambiguous genitalia CYP21A2 Adrenal hyperplasia, 
congenital, due to 21- 
hydroxylase deficiency 
#201910
Short long bones COL2A1 Achondrogenesis, type II 
#200610
Polycystic renal dysplasia ANKS6 Nephronophthisis 16 
#615382
Short long bones FGFR3 Achondroplasia #100800 LUTO/hydronephrosis, 
anhydramnios
FRAS1 Fraser syndrome 
#219000
Micrognathia COL1A1 Marshall syndrome 
#154780
CNS (4)
Micro-retrognathia COL2A1 Stickler syndrome type 1 
#108300
Macrocephaly, frontal bossing PIK3CA Megalencephaly-capillary 
malformation syndrome 
(M-CAP) #602501
Signs of arthrogryposis ECEL1 Distal arthrogryposis type 
5D #615065
Dysgenesis of corpus callosum FLNA Periventricular nodular 
heterotopia and corpus 
callosum hypoplasia 
#300049
Unilateral reduction defect 
of the upper extremity








brain and eye anomalies 
type A) #614643
Signs of skeletal dysplasia, 
hand and foot anomalies, 
polydactyly, short long 
bones and short ribs
EVC Ellis van Creveld syndrome 
#225500
Lissencephaly DCX Subcortical laminar 
heterotopia, X-linked, 
included double cortex 
syndrome #300067
(Continues)
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Indication for prenatal 
testing Gene
Molecular diagnosis
Phenotypic MIM number Indication for prenatal testing Gene
Diagnosis
Phenotypic MIM number
Short long bones, bell-
shaped thorax
FGFR3 Thanatophoric dysplasia 
type I #187600
NT ≥ 3.5 mm (3)
Major anomaly accompanied by a soft marker in another system (6) 3 cases: NT 3.6 mm, NT 
8.3 mm, NT 8.0 mm
PTPN11 Noonan syndrome 
#163950
Hydrops fetalis, ascites, 
echogenic bowel
CFTR Cystic fibrosis #602421 Multiple system anomalies
Ventriculomegaly, echogenic 
bowel
SOX2 Microphthalmia, syndromic 
3 #206900
NT 9.3 mm, cardiac anomalies PTPN11 Noonan syndrome 
#163950
IUGR, echogenic bowel, 
short femoral bones
SKIV2L Trichohepatoenteric 
syndrome (THES) type 2
#614602
Hydrops fetalis, complex 
cardiac anomalies, abnormal 
intracranial anatomy
PTPN11 Noonan syndrome 
#163950
Short long bones and 
bilateral pyelectasis
H19 Silver-Russell syndrome 
#180680
NT 8.0 mm and unilateral 
talipes
RAF1 Noonan syndrome 
#611553
SUA, pyelectasis, asymmetric 
ventriculomegaly
ZEB2 Mowat-Wilson syndrome 
#235730
Dandy Walker malformation, 
polycystic renal disease, 
oligohydramios
CEP290 Joubert syndrome type 5 
#610188
Bilateral talipes, varix vena 
umbilicalis






dysplastic renal disease, 
anhydramnios, ascites
CEP290 Joubert syndrome 
#610188
Cardiovascular (2) Craniofacial defect, semi-
lobar holoprosencephaly, 
encephalocele, retrognathia, 
bilateral (multiple) renal 
cysts, deformity of the hands 
and feet.
CC2D2A Joubert syndrome 9 
#612284 or Meckel 
Gruber syndrome 6 
#612284)
Complex cardiac anomaly MASP1 3MC syndrome 1 #257920 NT 4.6 mm, AVSD, absence 
cavum septi pellucidi, severe 
vermian defect,
ARID1A Coffin- Siris syndrome 
#614607
AVSD PTPN11 Noonan syndrome 
#163950
VSD, corpus callosum 
dysgenesis, ventriculomegaly
ARID1A Coffin-Siris syndrome 
#614607
Mild ventriculomegaly, 
dysgenesis of corpus 
callosum, rocker bottom 
foot, SUA
SMARCB1 Coffin-Siris syndrome 
#614608
Gastrointestinal (2) Spina bifida, oligohydramnios 
and IUGR
MANBA β-Mannosidosis #248510
Echogenic bowel, dilated 
intestinal loop





clubhand and clubfeet, VSD
HSPG2 Dyssegmental dysplasia, 
type Silverman-
Handmaker #224410







primordial dwarfism type 
1 #210710
Soft markers (1) Arthrogryposis, midline defect MYH3 Freeman-Sheldon 
syndrome (distal 
arthrogryposis type 2A) 
#193700
SUA, echogenic bowel CFTR Cystic fibrosis #602421 VSD, short femur, pyelectasis, 
and urinary bladder cyst
CREBBP Rubinstein- Taybi 
syndrome #180849
TA B L E  1   (Continued)
(Continues)
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onset ranges between infancy and adolescence. Individuals with 
β-mannosidosis can show intellectual disability, delayed motor 
development and epileptic seizures (MIM #248510). Both parents 
were found to be heterozygous for the pathogenic variant, which 
implicates a recurrence risk of 25%.
4  | DISCUSSION
The aim of this retrospective cohort study was to evaluate the po-
tential (additional) value of WES for explaining fetal anomalies found 
during the fetal anomaly scan. In our department, clinical geneticists 
select patients for additional molecular testing, so we were espe-
cially interested in the diagnostic yield in our selected population. 
Our data showed that in our patient group the potential diagnostic 
yield is high enough to offer prenatal WES at the time of invasive 
sampling. If this was done in our cohort 18.7% (95% CI 15.1%-22.8%) 
of the patients would receive a diagnosis already in pregnancy 
(Table 2), whereas when subsequent testing was employed the mean 
time until final diagnosis was 271 days after invasive testing. This 
is partially due to incompleteness of the fetal phenotype (targeted 
tests could be requested after birth or termination of pregnancy), 
subsequential character of testing (first targeted test, then broader 
test) and due to the parental requests to postpone the additional 
testing. In our cohort the large majority of cases (90.8%) underwent 
invasive sampling before the 24th week of gestation and early di-
agnosis by prenatal WES would likely contribute to the decision on 
continuation of pregnancy.
A systematic literature review revealed a broad range (6.2%-80%) 
of diagnostic yield in fetuses with structural anomalies across 16 
studies published in the period 2014-2017.14 Many of these studies 
included either severe multiple fetal anomalies or the families were 
highly selected (multiple affected fetuses, high percentage of consan-
guinity, selected type of anomalies).15-20 The high diagnostic yield of 
Alamillo et al (42.9%), Pangalos et al (42.9%) and Vora et al (46.7%) 
reflects the inclusion of fetuses with multiple congenital anoma-
lies.15,21,22 Careful selection by clinical geneticists indeed results in 
a very high diagnostic yield.23 Our study confirms that the potential 
diagnostic yield of WES in fetuses with multiple system anomalies is 
higher (29%, 95% CI 20.8%-38.9%) than the estimated yield in the 
group of (isolated) single system anomalies; however, the group of iso-
lated anomalies showed a substantial percentage of abnormal cases 
(16.7%, 95% CI 12.6%-21.8%). These results suggest that also fetuses 
with an isolated anomaly could be offered prenatal WES testing and 
Indication for prenatal 
testing Gene
Molecular diagnosis
Phenotypic MIM number Indication for prenatal testing Gene
Diagnosis
Phenotypic MIM number
Multiple system anomalies (27) Cleft hand/foot malformation, 
small abdominal 
circumference
H19 Silver-Russell syndrome 
#180680
SUA, AVSD, small abdominal 
circumference < P1
SETD5 Mental retardation (MRD) 
type 23 #615761
Hydrops fetalis, severe short 
extremities and retained 
curvature of the bones
COL1A1 Osteogenesis imperfecta 
type 2A #166210
Hydrops fetalis, complex 
cardiac anomalies
KMT2D Kabuki syndrome 1 
#147920
Microcephaly, IUGR DHCR7 Smith-Lemli-Opitz 
syndrome #270400
CL, tetralogy of Fallot, 
hypertelorism, hypospadias
MID1 Opitz G/BBB syndrome 
#300000
Nuchal fold, possible 
syndactyly, craniosynostosis 
(sutura coronalis sinistra)
FGFR2 Apert syndrome #101200
NT 7 mm, SUA, echogenic 
bowel, dilated LV abnormal 
mitralis valve, aortic valve 
with high PSV, cardiomegaly
NOTCH1 Adams-Oliver syndrome 
#616028
Exencephaly, bilateral 
enlarged cystic renal disease 
with no filling of the urinary 
bladder, bilateral talipes
CC2D2A Meckel syndrome type 6 
#612284
Bilateral enlarged kidneys, 
enlarged cisterna magna, 
ascites, pes equinovarus 
and oligohydramnios
BBS2 Bardet-Biedl syndrome 
#209900
complex cardiac anomalies, 
abnormal fossa posterior, 
abdominal cyst
CHD7 CHARGE syndrome 
#214800
Bilateral cleft palate and lip, 
polydactyly,
nuchal fold thickening, 
echogenic focus within 
heart, stenosis of the arteria 
pulmonalis, mild tricuspid 
valve insufficiency and 
stenosis
CEP164 Nephronophthisis 15 
#614845
Prefrontal edema, ascites, 
hypoplastic nose, 
kyphoscoliosis thoraco-
lumbar, bilateral rocker 
bottom feet, bilateral 
clenched hands, short long 
bones < p5, bell-shaped 
thorax
COG5 Congenital disorder of 
glycosylation type IIi 
(CDG2i) #613612
Abbreviations: AVSD, atrioventricular septal defect; CL, cleft lip; CNS, central nervous system; IUGR, intrauterine growth restriction; LUTO, lower 
urinary tract obstruction; LV, left ventricle; NT, nuchal translucency; PSV, persistent sciatic vein; SUA, single umbilical artery; VSD, ventricular septal 
defect.
TA B L E  1   (Continued)
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confirms that patient selection based on the prenatal phenotype may 
be challenging.24
The cohort selection may be the major reason for the large 
variation in the incidence of pathogenic WES findings in the co-
horts published so far in the literature. In our cohort with a wide 
range of phenotypes that are typically seen in the clinic cohort, 
18.7% (95% CI 15.1%-22.8%) of patients showed DNA variants 
that could have been detected by WES. Although WES was not 
performed in all cases, our results are similar to the percentage 
found by Fu et al25 Due to our cohort size and the subgroups of 
fetal anomalies, our estimated diagnostic yield showed a relatively 
wide confidence interval in some cases, which indicates that these 
estimates should be interpreted with caution. The large prospec-
tively tested cohorts that have recently been published by Lord 
et al26 and Petrovski et al27 show lower prevalence of pathogenic 
findings (8.5% and 10%, respectively). Neither cohort was selected 
by clinical geneticists and patients were invited to participate after 
ultrasound anomalies were found. These studies confirm that in 
unselected fetuses with ultrasound anomalies the diagnostic yield 
of WES testing is high enough to conclude that prenatal WES 
would be of great clinical value if offered simultaneously with 
chromosomal microarray.
TA B L E  2   The diagnostic yield rates in our cohort subdivided into major categories, the diagnostic yields after Noonan syndrome and 





Overall DY Overall without Noonan/CF cases
Overall potential DY of WES if applied instead 
of targeted testing
N DY rate; % (95% CI)
No. of Noonan 
and CF cases n DY rate; % (95% CI)
No. of Silver-
Russell casesa  n DY rate; % (95% CI)
(1) ISS 42/251 16.7% (12.6%-21.8%) 11 31/240 12.9% (9.3%-17.8%) 1 41/251 16.3% (12.3%-21.4%)
(2) MA 6/26 23.1% (11.0%-42.1%) 1 5/25 20.0% (8.9%-39.1%) 1 5/26 19.2% (8.5%-37.9%)
(3) MSA 27/93 29.0% (20.8%-38.9%) 3 24/90 26.7% (18.6%-36.6%) 1 26/93 28.0% (19.9%-37.8%)
(4) SM 1/21 4.8% (0.8%-22.7%) 1 0/20 0.0% (0.0%-16.1%) 0 1/21 4.8% (0.8%-22.7%)
All cases 76/391 19.4% (15.8%-23.6%) 16 60/375 16.0% (12.6%-20.1%) 3 73/391 18.7% (15.1%-22.8%)
Abbreviations: CF, cystic fibrosis; CI, confidence interval; DY, diagnostic yield; ISS, (isolated) single system anomalies; MA, multiple anomalies (1 
system + soft marker in another organ system); MSA, multiple system anomalies; SM, soft marker(s) only; WES, whole exome sequencing.
aCases of abnormal methylation would still remain undetected if prenatal WES was implemented. 
F I G U R E  1   Number and percentage 
of cases with a molecular diagnosis per 
ultrasound category. The total number of 
tested cases was 391. ISS, (isolated) single 
system; MA, major anomaly accompanied 
by a soft marker in another system; MSA, 
multiple system anomalies
F I G U R E  2   Number and percentage 
of cases with a molecular diagnosis 
per category of (apparently) isolated 
anomalies. The total number of cases with 
(apparently) isolated anomalies was 251. 
IUGR, intrauterine growth restriction; 
CNS, central nervous system; NT, nuchal 
translucency
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In our cohort, some of the fetuses had ultrasound anomalies 
suggestive for a known genetic disease for which rapid standard 
targeted testing is available, for example, cystic fibrosis and Noonan 
syndrome. Therefore, one could consider employing a targeted test 
first to exclude certain disorders. However, when there is a legal limit 
for termination of the pregnancy it may not be feasible to first re-
quest a targeted test and if that is normal then to proceed with WES. 
Therefore, we have hypothesized that it might be interesting to con-
sider replacing all targeted tests in pregnancy with WES and obtain 
diagnosis of all syndromes possibly detected by WES in one test as 
early as possible. In the Netherlands, the legal limit for pregnancy ter-
mination is the 24th week of gestation and therefore only if the fetus 
is sampled in the first trimester would first a targeted test and then 
subsequent WES testing be feasible. In our cohort, only testing for 
Noonan syndrome (in the first or early second trimester in cases with 
neck anomalies) would be feasible before WES request. In our cohort 
among 79 cases with apparently isolated nuchal translucency, three 
cases of Noonan syndrome were detected, therefore we hypothesize 
that in the first trimester the dedicated Noonan NGS panel could be 
performed and then only in cases showing additional anomalies, WES 
analysis could follow in the second-trimester. However, although such 
a two-step procedure is feasible in the first trimester, it is unfavorable 
for patients who wish to receive a final diagnosis as soon as possible.
While offering prenatal WES testing, we should be aware of its 
technical limitations. These technical limitations imply that repeat 
expansions will not be detected and small (one or two) exon dele-
tions and single nucleotide variants in poorly covered regions may be 
missed.28 As shown in this study, methylation disorders will remain 
undetected as well. Prenatal WES can detect many syndromes, but 
certainly cannot exclude all genetic diseases, which should be ad-
dressed in pre- and posttest counseling.
Another limitation is the incomplete fetal phenotype as deter-
mined by prenatal imaging. In some cases variants may remain of 
unknown significance until more phenotypic data become available 
after birth. For this reason, during pregnancy, it may be difficult to 
conclude that the genotype is causal, especially if the variant is pre-
viously not described. Lord et al. presented several genes identified 
in their cohort that had diagnostic variants without previous prena-
tal phenotype descriptions.26
The possibility of re-interpretation of variants after more data 
become available should be discussed during pretest counseling as 
well. Efforts to share genotypes and prenatal phenotypes in data-
bases should be made to further reduce the uncertainty related to 
several genetic variants and facilitate data interpretation. Because 
of the incomplete fetal phenotype, more studies are necessary to 
assess which approach is the most suitable in the prenatal setting: 
WES or a specific broad gene panel analysis.
An often-discussed issue of any whole genome testing is the pos-
sibility of reporting the so-called unexpected diagnoses or incidental 
findings that seem to be unrelated to the initial indication. In our 
cohort only one unexpected diagnosis was made and it concerned an 
early onset disorder. Unexpected diagnoses are not new in the con-
text of prenatal testing, as it is known from the era of karyotyping 
as well as chromosomal microarray, but proper pretest counseling 
should always be provided, so that the unexpected character of such 
a finding can be reduced.29
The retrospective character of this data analysis is the major lim-
itation. The percentages of cases with a genetic diagnosis are based 
on different tests that were performed in different stages of preg-
nancy or after delivery. A large number of cases proceeded only to 
targeted sequencing (n = 232) which may cause underestimation of 
the number of abnormal fetal cases. Broad molecular testing was 
performed in some cases (n = 159), where potentially an underlying 
monogenetic disorder could be identified and where parents wished 
to proceed with further diagnostics. Some of the patients refused to 
proceed to molecular testing if the results were not available before 
the 24th week of gestation. Therefore, the presented data may differ 
from cohorts prospectively tested with WES.
5  | CONCLUSION
Our retrospective cohort study shows that WES, if routinely offered 
by a clinical geneticist to patients in a prenatal setting, would sig-
nificantly increase the diagnostic yield. Prenatal WES could lead to 
early diagnosis of a genetic disorder in a significant percentage of 
cases irrespective of the (incomplete) fetal phenotype. We assumed 
that only when an anomaly is detected in the first trimester, it may 
be feasible to request targeted tests before broad genetic testing, 
otherwise there may not be time to perform subsequent panel or 
whole exome analysis (if there is a legal limit for terminating an af-
fected pregnancy).
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